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ABSTRACT 
Transient reduction in coronary perfusion pressure in the isolated mouse heart 
increases microvascular resistance (paradoxical vasoconstriction) by an endothelium-
mediated mechanism. To assess the presence and extent of paradoxical 
vasoconstriction in hearts from normal and diabetic rats and to determine whether 
increased heme oxygenase (HO)-1 expression and HO activity, using cobalt 
protoporphyrin (CoPP), attenuates coronary microvascular response. Male Wistar rats 
were rendered diabetic with nicotinamide/streptozotocin (NA/STZ) for 2 weeks and 
either CoPP or vehicle was administered, by intraperitoneal injection, daily for 3 weeks 
(0.5 mg/100 gm body wt). The isolated beating non-working heart was submitted to 
transient low perfusion pressure (20 mm Hg) and coronary resistance (CR) was 
measured. During low perfusion pressure, CR increased and was associated with 
increased lactate release. In diabetic rats, CR was higher, HO-1 expression and 
endothelial nitric oxide synthase (eNOS) were downregulated, and inducible nitric oxide 
synthase (iNOS) and superoxide anion (O2
-) were upregulated. After 3 weeks of CoPP 
treatment, HO activity was significantly increased in the heart. Upregulation of HO-1 
expression and HO activity by CoPP resulted in the abolition of paradoxical 
vasoconstriction and a reduction in oxidative ischemic damage. In addition, there was a 
marked increase in serum adiponectin. Elevated HO-1 expression was associated with 
increased expression of cardiac eNOS, B-cell leukemia/lymphoma extra long (Bcl-xL) 
and phospho activator protein kinase (pAKT) levels, and decreased levels of iNOS and 
malondialdehyde (MDA). These results suggest a critical role for HO-1 in microvascular 
tone control and myocardial protection during ischemia in both normal and mildly 
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diabetic rats through the modulation of constitutive and inducible nitric oxide synthase 
expression and activity, and an increase in serum adiponectin. 
 
Key words: antiapoptotic signaling protein, superoxide anion, phosphorylated Akt, 
heme oxygenase, adiponectin 
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INTRODUCTION 
According to classical concepts of autoregulation, coronary microvessels dilate in 
response to a reduction in perfusion pressure so as to preserve flow. Beneath a certain 
pressure level, the exhaustion of this mechanism causes flow to decline and myocardial 
ischemia to ensue. Recently, both clinical and experimental studies (26; 48) have 
demonstrated a “paradoxical” coronary microvascular constriction during severe 
reduction in perfusion pressure and myocardial ischemia. It is not known whether this 
may be a naturally occurring response to severe hypotension and ischemia, possibly 
intended to preserve capillary pressure, or whether it may be caused or enhanced by 
the presence of endothelial dysfunction, hence, aggravating myocardial ischemia. 
In the isolated mouse model, “paradoxical coronary vasoconstriction” has been 
reproduced by perfusion at low pressure and the endothelium appears to play a pivotal 
role in this vascular response, which involves the cooperative vasoconstrictive actions 
of the nitric oxide (NO) and endothelin systems (26). In particular, nitric oxygen 
synthase (NOS) inhibition or the administration of reactive oxygen species (ROS) 
scavengers has been able to antagonize the paradoxical vasoconstrictive response to 
low pressure. This observation led to the hypothesis that, during ischemia, NO released 
in the vascular wall and possibly in the myocardium can be converted by ROS to a 
reactive species with constrictive properties, such as peroxynitrite, with a simultaneous 
reduction of NO availability and activation of the vasoconstrictive pathway of the 
endothelin. 
Type 2 diabetes is a clinical condition, the prevalence of which is rapidly growing 
in Western countries. It has been estimated that, by the year 2030, there will be almost 
Page 4 of 48
Copyright InformationHO-1 and coronary microcirculation 
 
4
30 million Americans with diagnosed diabetes (60). Evidence suggests that diabetes 
and insulin resistance are major risk factors for cardiovascular disease (39) due to the 
associated endothelial dysfunction and increased oxidative stress (57). Insulin 
resistance is associated with abnormal endothelium-dependent coronary vasomotion 
(44), which progressively worsens with progression to overt Type 2 diabetes (43). In 
experimental diabetes, there is an overproduction of ROS in the vascular wall that is 
thought to enhance NO degradation and promote the formation of peroxynitrite. The 
excessive ROS burden may thus promote atherogenesis by causing endothelial 
dysfunction in concert with inflammatory reactions and low density lipoprotein (LDL) 
oxidation (30). It has recently been reported that the actions of adiponectin, an anti-
diabetic, anti-atherogenic and anti-inflammatory adipokine (7; 8), are mediated through 
adiponectin receptors, and that genetic variations on the Adipo2 receptor are associated 
with increased adiponectin levels and decreased triglyceride levels in patients with 
metabolic syndrome (6).  
Adiponectin has been ascribed anti-oxidative properties (20); it improves 
endothelial function in patients with metabolic syndrome and also improves the 
beneficial effects of antihypertensive agents in hypertensive patients(40; 63). The 
concentration of adiponectin is reported to be decreased in coronary diseases and Type  
2 diabetes (19). Some aspects of clinical insulin resistance and Type 2 diabetes can be 
reproduced experimentally in rats by streptozotocin administration (STZ) and 
nicotinamide (NA) (27). It can be hypothesized that the presence of coronary endothelial 
dysfunction and/or increased ROS formation could influence the coronary vasomotor 
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response to low pressure ischemia in isolated hearts from STZ/NA rats as compared to 
normal controls. 
The recognition that heme oxygenase (HO)-1 is present in the heart and induced 
by various oxidants, including metals, signifies the importance of this enzyme in 
cradioprotection (37;3). Cardioselective overexpression of HO-1 exerts a 
cardioprotective effect after myocardial ischemia-reperfusion in mice (55). The robust 
ability of HO-1 to protect against oxidative insult in cardiovascular diseases, including 
diabetes, suggests that HO-1 may be a target for pharmacological intervention in the 
alleviation of vascular diseases (1). The protective effects of HO-1 arise from its 
capacity to increase degradation of the heme moiety from destabilized heme proteins 
(36) and to generate biliverdin and bilirubin, which possess potent antioxidant properties 
(51) and display cytoprotective properties in the cardiovascular system (10; 18). Carbon 
monoxide (CO) is not an antioxidant (59) but has a beneficial effect on vascular 
relaxation and causes the induction of antioxidant genes, including superoxide 
dismutase and glutathione levels (1; 13; 46; 53).   
 
Recently, Nishikawa et al. have shown that the HO-CO pathway is involved in 
ischemic vasodilation in the coronary microcirculation  (38). Yet et al. reported the 
occurrence of severe right ventricular enlargement after chronic hypoxia in HO-1-
deficient compared to wild-type mice (61) and that the cardiac-specific expression of 
HO-1 protects against ischemia and reperfusion (62). Further, HO-1 gene expression 
has been shown to reverse neointimal hyperplasia (21) and ischemic heart injury (16), 
and prevent vascular dysfunction in experimental diabetes (24) [for review see (1)]. 
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These effects were related to an increase in the HO-CO pathway and to the associated 
increase in eNOS and reduction in iNOS expression; thus, both improving endothelial 
function and decreasing overall NO availability for peroxynitrite formation (1; 2; 13; 53). 
The aims of this study were to assess the presence and extent of paradoxical 
vasoconstriction and its influence on ischemia in hearts from normal and mildly diabetic 
rats, to determine whether the upregulation of HO-1 accompanied by increased HO 
activity modulates coronary microvascular tone and myocardial ischemia, and to 
examine the possible mechanism(s) involved. 
Page 7 of 48
Copyright InformationHO-1 and coronary microcirculation 
 
7
MATERIALS AND METHODS 
All experiments were approved by the Institutional Animal Care and Use 
Committee and conducted under the guidelines for the Care and Use of Laboratory 
Animals, published by the Office of Science and Health Reports, National Institutes of 
Health. 
Induction of diabetes. Male Wistar rats, 2-3 months of age, received 210 mg/kg of 
nicotinamide dissolved in saline (NA; Sigma, St. Louis, MO) intraperitoneally 15 min 
before an intravenous injection of streptozotocin 60 mg/kg (STZ; Sigma, St. Louis, MO) 
dissolved in citrate buffer (pH 4.5) immediately before use to obtain a mild and stable 
diabetes with reduced beta-cell mass (28). The resulting mild diabetes did not require 
insulin. This experimental model has been utilized as a model for non-insulin-dependent 
diabetes mellitus  (NIDDM) syndrome and is regarded as similar to human Type 2 
diabetes in that it has a significant response insulin responsiveness to glucose, 
preserved sensitivity to tolbutamide and provides partial pancreatic protection (9; 28). 
Each set of NA/STZ-treated animals was matched by one group of controls receiving 
vehicle. After two weeks, the average plasma glucose level in NA/STZ rats was 149±3.6 
mg/dl and the corresponding plasma insulin level was 1.40±0.14 ng/ml compared to 
108±2.6 mg/dl and 1.87±0.40 ng/ml, respectively, in rats receiving vehicle (p<0.01 and 
ns, respectively). Cobalt protoporphyrin (CoPP) (0.5 mg/100 g) or the corresponding 
vehicle was given subcutaneously once a week for three additional weeks. Hence, four 
subgroups of animals were studied: control rats (C, n=18), mildly diabetic rats (D, n=24), 
control rats- CoPP (C-CoPP, n=8), and mildly diabetic rats- CoPP (D-CoPP, n=11).  
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Isolated heart preparation. Rats were anaesthetized with a mixture of ether and 
air and heparinized via the left femoral vein (250 units/kg) 72 hours after the last CoPP 
or vehicle injection. The heart was rapidly excised and placed in perfusion medium. 
Within 30 sec, the aorta was attached to a stainless steel cannula, the pulmonary artery 
was incised to permit adequate drainage, and the heart was perfused normothermically 
(37ºC) by the method of Langendorff at a perfusion pressure equivalent to 80 mm Hg. 
The perfusion medium was Krebs-Henseleit buffer (KHB) having the following 
composition in mM: NaCl 120.0, NaHCO
- 25.0, KCl 4.8, MgSO4.7H2O 1.2, KH2PO4 1.2, 
glucose 11, CaCl2.2H2O 1.4 (pH 7.4 when gassed with 95% O2 and 5% CO2). 
Experimental protocols. The time course of coronary resistance (CR) and 
lactate release were obtained according to the above protocol and were compared with 
those from isolated hearts continuously perfused with oxygenated KHB for 80 min at 80 
mm Hg pressure. Isolated hearts were perfused with oxygenated KHB for 20 min at 80 
mm Hg pressure, then perfusion pressure was decreased to 20 mm Hg for 30 min, and 
then pressure was increased back to 80 mm Hg for the remaining 30 min (reperfusion). 
In all experiments, coronary flow was measured continuously with the volume of 
effluent calculated with a calibrated pipette. CR was defined as input pressure divided 
by coronary flow per gram of myocardial tissue (mmHg · min · g · mL
-1). For successive 
analyses, data relative to the first 10 min of perfusion (stabilization period) were 
discarded. At different times, coronary perfusate was collected and lactate 
concentration was determined in the perfusion medium. At the end of each experiment, 
the heart was rapidly frozen in liquid nitrogen and then stored at -80
oC. 
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Lactate quantification. Lactate concentration was measured by the automated 
spectrophotometric enzymatic method on a Beckman CX4 Synchron Analyzer 
(Fullerton, CA) (17). The between assay coefficient of variation was 5% and the 
detection limit was 0.05 µMol.  
Malondialdehyde (MDA) determination. Frozen hearts were pulverized under 
liquid nitrogen and homogenized in an acid solution (perchloric-acetic acid 0.6M). 
Homogenates were centrifuged at 13,000 x g for 15 min at 4ºC, supernatant was 
isolated, and protein levels were assayed by the Bradford method. One volume of 
supernatant was mixed with 1 volume of 0.66% (w/v) thiobarbituric acid (TBA), and the 
mixture was boiled for 15 min. After cooling in tap water, the mixture was read at 535 
nm, and the TBA-MDA adduct was calculated by using a molar absorption coefficient of 
1.56 x 10
5 M
-1/cm (35). 
Determination of HO, eNOS, iNOS, pAKT and serum adiponectin. Frozen 
hearts were pulverized under liquid nitrogen and placed in a homogenization buffer (10 
mM phosphate buffer, 250 mM sucrose, 1 mM EDTA, 0.1 mM PMSF and 0.1% tergitol, 
pH 7.5). Homogenates were centrifuged at 27,000 x g for 10 min at 4ºC, supernatant 
was isolated, and protein levels for HO-1/HO-2, eNOS, iNOS and pAkt, as well as O2
-
levels and HO activity, were measured as previously described (5; 24). Adiponectin 
assayed in serum obtained from venous blood samples obtained immediately before 
heart excision was determined using ELISA assay (Pierce Biotechnology, Inc, Woburn, 
MA). 
Statistical analysis. Results are presented as mean ± standard error (SE) for 
the number (n) of replicate determinations. Statistical significance between experimental 
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groups and between different study conditions was determined by using a two-way 
ANOVA followed by the Fisher’s exact test; p<0.05 was considered significant.  
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RESULTS 
Coronary resistance and effect of CoPP. In both control (C) and diabetic (D) 
animals, CR tended to remain constant during the 80 min perfusion period at constant 
pressure. When the perfusion pressure was suddenly decreased to 20 mm Hg, CR 
rapidly increased in both groups by 1.6-fold (p<0.01 vs. baseline) and remained high for 
the entire period of low perfusion pressure. During early reperfusion (first minute), CR 
promptly decreased to below baseline values (p<0.01 vs. baseline), then progressively 
increased, stabilizing after 10 min at baseline values in C rats and slightly over baseline 
values in D rats (Figure 1 and Table 1). This demonstrates the presence of a 
vasoconstrictive response during transient low perfusion pressure (paradoxical 
vasoconstriction) followed by vasodilation (reactive hyperemia) at the onset of 
reperfusion in both groups. CR was higher in D rats than in C rats under all study 
conditions (p<0.01), except during reactive hyperemia. 
In both C-CoPP and D-CoPP animals, CR tended to remain constant during the 
80 min perfusion period at constant pressure. During transient low perfusion pressure, 
CoPP was able to completely abolish paradoxical vasoconstriction in both C and D 
animals, leaving the maximal reactive hyperemic response (minimal resistance values) 
unchanged (Figure 1). Compared to untreated animals, CoPP increased CR values at 
baseline (p<0.01) and in the late phase of reperfusion (p<0.01). CR was higher in D-
CoPP than in C-CoPP rats under all study conditions (p<0.01), except reactive 
hyperemia (Table 1), when considering absolute values. However, if the percentage 
increase is considered, then the difference between control and diabetic animals is 
significantly decreased (p<0.01). 
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Myocardial lactate release and effect of CoPP. During perfusion at constant 
pressure, no myocardial lactate release was measured in any animal. The absence of 
lactate release was also noted during baseline as well as during the late reperfusion 
period of the transient low perfusion pressure protocol. Conversely, during the low-
pressure perfusion period, myocardial lactate release was documented in all groups 
(Figure 2). Lactate release was similar in C and D animals and it significantly decreased 
following CoPP in both (C-CoPP and D-CoPP) groups (p<0.01). In D-CoPP animals, 
lactate release decreased to half the levels measured in the untreated D animals. At 
early reperfusion, hearts from C and D rats showed a significant peak of lactate release 
(p<0.01 vs. baseline and vs. low-pressure perfusion), which was abolished following 
CoPP treatment (Figure 2). The total amount of lactate released (integral of the curves 
in Figure 2) was 14.9+/-1.3 µMol/g in C and 12.8+/-1.32 µMol/g in D animals (p=0.29). 
Following CoPP, lactate release was reduced to 6.1+/-0.92 µMol/g in C-CoPP and to 
4.57+/-0.74 µMol/g in D-CoPP animals (p<0.01 C vs. C-CoPP and D vs. D-CoPP). 
Cardiac HO-1 and effect of CoPP. In both control and diabetic hearts, 
pretreatment with CoPP caused an increase in HO-1 protein levels (p<0.01, C-CoPP 
and D-CoPP vs. C and D, respectively) and an increase in HO activity (p<0.01, C-CoPP 
and D-CoPP vs. C and D, respectively) (Figure 3). Diabetic hearts, as compared to 
control hearts, displayed lower levels of HO-1 protein (p<0.05 D vs. C). Diabetes did not 
influence the levels of HO-2 protein (Figure 4). As seen in Figure 3, HO activity was 
significantly lower in diabetic hearts compared to controls (p<0.05 D vs. C). 
Cardiac eNOS and iNOS levels and effect of CoPP. Compared to untreated 
controls, untreated diabetic hearts showed lower levels of eNOS protein (p<0.05) and 
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higher values of iNOS protein (p<0.05) (Figure 5). The increases in HO-1 protein and 
total HO activity by CoPP resulted in enhanced expression of eNOS protein (p<0.05 
compared to control) and reduced expression of iNOS protein in both diabetic and 
control hearts (Figure 6). 
Cardiac MDA and serum adiponectin levels after transient reduction of 
perfusion pressure and effect of CoPP. MDA levels were similar in hearts obtained 
from D and C rats after transient low pressure. As a result of CoPP administration, MDA 
levels were decreased by 50% in C-CoPP and by 45% in D-CoPP rats (p<0.01 CoPP-
treated groups vs. corresponding controls) (Figure 7).  
Adiponectin levels were lower in diabetic (3.88±1.04 µg/ml) compared to 
7.1±0.76  µg/ml in control rats (p<0.05). CoPP administration significantly increased 
serum adiponectin (to 12.7±2.56 µg/ml) in diabetic rats compared to untreated diabetic 
rats (p<0.01). To ascertain whether the CoPP-mediated increase in adiponectin levels 
was related to increased HO activity, we co-administered SnMP (tin mesoporphyrin), an 
inhibitor of HO activity, to D-CoPP rats, which resulted in inhibition of HO activity and 
serum adiponectin release (data not shown). 
Cardiac O2
- levels and effect of CoPP. O 2
- measurements, using 
chemiluminescence, were performed at low concentrations of lucigenin (5 µM) in hearts 
obtained at the end of the transient low-pressure experiments. Diabetic hearts showed a 
significant increase in O2
- compared to controls (p<0.05 D vs. C). Treatment with CoPP 
caused a decrease in O2
- in diabetic hearts (p<0.01 D-CoPP vs. D), which is in close 
association with the increase in HO-1 activity (Figure 3). 
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Bcl-xL and pAkt expression and the effect of CoPP. The induction of diabetes 
resulted in no significant changes in BcL-xL, AKT, and phosphorylation of AKT (pAKT) 
expression. CoPP administration had no effect on AKT expression; however, there was 
a significant increase in the expression of pAKT and Bcl-xL in both C-CoPP and D-
CoPP animals (Figure 9). The changes in protein expression of Bcl-xL and pAKT 
mirrored those seen with HO-1 protein expression. 
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DISCUSSION 
This is the first report to demonstrate, in hearts isolated from normal and mildly 
diabetic rats, that paradoxical coronary vasoconstriction, occurring during low pressure 
ischemia, can be reversed by HO-1 induction through modulation of NOS isoforms and 
a decrease in superoxide (O2
-) production. In addition, serum levels of the adipokine, 
adiponectin, increased as a result of HO-1 induction and increased HO activity. 
We used coronary hypoperfusion in isolated rat hearts to reproduce a 
microvascular vasoconstrictive response similar to what has been documented by our 
group in the isolated mouse heart (26). In this study, we also clearly demonstrated the 
occurrence of myocardial ischemia during low perfusion pressure, as evidenced by the 
prompt and consistent release of lactate. Thus, in spite of the documented ischemia, 
coronary microvascular tone increased, challenging the traditional view of maximal 
vasodilation during restricted flow and justifying the term ”paradoxical vasoconstriction” 
to define such a phenomenon. This is the expression of an active increase in vascular 
tone as previously shown by the prompt reversal via papaverine or adenosine and by 
manipulation with eNOS inhibitors, endothelin blockade and antioxidants (26). 
In the present study, paradoxical vasoconstriction was also observed, for the first 
time, in hearts isolated from mildly diabetic rats, which showed higher coronary 
resistance values compared to controls under all conditions studied and when 
considering absolute values (Table 1). The changes decrease when considered as a 
percentage; however, this comparison also shows higher coronary resistance values in 
diabetic animals compared to controls. As judged by lactate release, no striking 
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differences were apparent between control and diabetic animals in the severity of 
ischemia induced by perfusion at low pressure.  
  A major finding of the study is that pharmacological induction of HO-1 expression 
and increased HO activity, by CoPP, completely prevented paradoxical vasoconstriction 
in both control and diabetic rats and decreased lactate release, an effect that was 
particularly evident in the diabetic group. After CoPP administration, there is a clear 
reduction in both MDA and superoxide in diabetic hearts; conversely, MDA is reduced 
but superoxide is not reduced in the normal hearts. This may be due to several factors. 
For example, NADPH oxidase, which is a critical source of superoxide, may be present 
at low levels in the normal heart and CoPP may not further decrease superoxide 
production in control animals, as it is already very low. In diabetes, in contrast to normal 
groups, there is activation of NADPH oxidase and mitochondrial production of ROS, 
which is prevented by CoPP. Additionally, vasoconstriction may not come from 
superoxide only but from the inflammatory molecules TGF and Ang II under 
hyperglycemic conditions [for review see (1)]. Regardless, the CoPP-mediated increase 
in HO- 1 supports the view that paradoxical vasoconstriction modulates the severity of 
ischemia and that its pharmacological control might be beneficial to the preservation of 
myocardial metabolic homeostasis. 
Several potential molecular mechanisms involved in the striking effect of HO-1 
induction on coronary microvascular response to low perfusion pressure were also 
explored. After the transient reduction of perfusion pressure, hearts from mildly diabetic 
rats showed, as compared to controls, lower expression of both HO-1 and eNOS, higher 
expression of iNOS and higher cardiac O2
- levels, similar to that previously reported in 
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hearts from severely diabetic animals not submitted to acute changes in coronary 
hemodynamics (24; 53). The CoPP-mediated induction of HO-1 significantly increased 
eNOS and decreased iNOS protein levels in both control and diabetic rats. In diabetic 
rats, CoPP increased HO-1 expression, HO activity, serum adiponectin levels, eNOS, 
pAKT, and the antiapoptotic protein BcL-xL compared to controls, and these changes 
correlated with a significant decrease in O2
- levels. Taken together these results 
suggest that HO-1 involvement in the regulation of coronary microvascular tone is 
mediated by the modulation of NOS isoforms and control of oxidative stress. 
There are numerous possible mechanisms by which the HO-1/HO-2 pathway 
may improve vascular function. Nishikawa et al. have suggested that HO-2 activation 
may occur in ischemic hearts in dogs and that inhibition of the HO system by SnMP 
inhibits vasodilation during ischemia in the presence of NO and COX inhibitors (38). 
CO-releasing molecules, i.e., CORM-3, prevent ischemic damage (16). CO also 
protects isolated hearts against ischemia-reperfusion (11). Ischemic and non-ischemic 
cardiomyopathy patients’ exhaled CO levels lower than that of healthy controls at rest 
and after exercise. Guo et al. have presented evidence that CO, one of the products of 
HO-1-derived activity, was able to reduce infarct size (16). Di et al and Rodella et al , 
have shown that increased CO levels have a beneficial effect on vascular relaxation and 
prevent endothelial cell death (13; 45). In addition, Kruger et al. have shown that 
upregulation of HO-1 may improve vascular function by increasing superoxide 
dismutase and catalase activity and reducing tissue O2
- levels (24; 53). Hyperglycemia 
and ischemia enhance endothelial O2
- production, leading to increased vascular 
formation of the NO/superoxide reaction product, peroxynitrite (12; 22; 34). Peroxynitrite 
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oxidizes the active NOS cofactor, tetrahydrobiopterin, to cofactor inactive molecules, 
such as dihydrobiopterin (32). This uncouples the enzyme, which then preferentially 
increases O2
- production over NO production (32; 58). The HO-1 gene expression-
mediated decrease in O2
- may, in turn, lead to protecting eNOS from uncoupling. 
Bilirubin, another heme degradation product, may have vascular protective effects as 
well. Numerous reports indicate that a higher serum bilirubin level is related to a 
decrease in lipid peroxidation and is associated with a decrease in the risk for coronary 
artery disease in humans (49; 54). The benefits of bilirubin as an antioxidant and 
cytoprotective agent have been reviewed (1).  
In the present study, CoPP administration to diabetic rats resulted in a significant 
increase in serum adiponectin levels, which was blocked by the administration of the 
HO inhibitor SnMP. This increase in adiponectin may precondition the heart to be more 
resistant to oxidative stress. The existence of an adiponectin-HO-1 axis may explain the 
direct effect of adiponectin alone on the observed increase in  pAKT. Serine/threonin 
protein kinase AKT/PKB is recognized as a key regulator of cell endothelial cell survival, 
growth and migration (15; 33; 47). More recently, activation of pAKT was reported to 
promote the survival/proliferation of endothelial cells (50; 64). Ouchi et al. and others, in 
a series of elegant studies, have reported that adiponectin is critical for endothelial cell 
survival and function (25; 41; 42). A decrease in circulating adiponectin levels was 
reported in patients with metabolic syndrome (6) and was linked to higher mortality in 
ischemic congestive heart failure patients (52). Adiponectin levels increased after 
rosiglitazone treatment in non-diabetic individuals with metabolic syndrome with a 
resultant improvement of endothelial function (4; 63). Polymorphisms at the adiponectin 
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locus have been reported to be predictors of circulating adiponectin levels, insulin 
sensitivity and atherosclerosis (31). Adiponectin has been reported to protect against 
apoptosis via increased expression of superoxide dismutase and catalase, and 
regulation of Bcl-2 and Bax expression (20).  
Thus, the effect of CoPP treatment increasing adiponectin levels in diabetic 
animals, which we report here, suggests the possible beneficial role of adiponectin in 
diabetes. This conclusion stems from the fact that the HO-1-mediated increase in 
adiponectin provides the heart with a tolerance to oxidants  thus enabling the isolated 
heart to be resistant to stress situations. It is therefore possible that, in addition to 
increased levels of bilirubin (anti-oxidant) and CO (anti-apoptotic), compounds regarded 
as cytoprotective, observed after HO-1 induction, increased levels of adiponectin also 
function to protect the cell against toxic insults. This is the first report to demonstrate 
that increased levels of adiponectin are associated with the induction of HO-1 and, as 
such, offer a new therapeutic approach to the treatment of diabetes. 
The present study establishes the direct action of HO-1 in enhancing eNOS while 
downregulating iNOS cardiac protein levels in this model of low-pressure ischemia. 
These effects were closely associated with an improvement of coronary microvascular 
response to a transient reduction in perfusion pressure, as shown by the abolition of 
“paradoxical vasoconstriction”. These findings highlight the role of HO-1 in modulating, 
via multiple mechanisms, coronary vascular tone during ischemia. In circumstances 
associated with a marked decrease in antioxidant capabilities, such as in ischemia-
reperfusion or diabetes [for review(1)], increased levels of O2
- scavenge NO. As a result, 
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NO bioavailability in the vascular system decreases and peroxynitrite formation 
increases, potentially leading to reduced vasodilating properties.  
High levels of HO-1 in blood vessels and in the myocardium may, therefore, 
antagonize vasoconstriction by modulating NOS isoforms expression in favor of eNOS 
vs. iNOS and by diminishing extracellular O2
- through an enhancement of antioxidant 
systems. In our study the overall effects of CoPP in counteracting myocardial oxidative 
stress was particularly evident in diabetic animals where both myocardial O2
- and MDA 
levels were significantly reduced after treatment. In control animals CoPP still reduced 
MDA levels but did not change O2
- levels. We don’t have an explanation for this 
discrepancy. It is possible that detectable changes in O2
- require large differences, as 
in diabetes, while changes in MDA (an integrated measure of oxidative stress) are more 
sensible. Additionally, vasoconstriction may not come from superoxide but from the 
inflammatory molecules TGF and Ang II under hyperglycemic conditions, which is not 
increased in control animals. 
The role of Bcl-xL and pAKT may also be crucial in mediating the observed 
favorable effect of CoPP treatment in this model of low-pressure ischemia. Fujio et al. 
have shown that AKT signaling is essential to protecting against apoptosis, limiting 
infarct size induced by ischemia-reperfusion injury, and promoting contractility and 
glucose uptake (14; 29). Additionally, an increase in pAKT may cause the acceleration 
of glucose uptake via glucose transporter-4(GLUT 4) translocation to plasma 
membranes (56), subsequently decreasing the rate of glucose oxidation and attenuating 
cardiac damage (23; 56). These results are in agreement with the present data in which 
CoPP causes a significant increase in pAKT and Bcl-xL levels, mirroring a marked 
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reduction in the myocardial metabolic effects of low pressure induced ischemia. Finally, 
for the first time, HO-1 induction was associated with a parallel increase in the serum 
levels of the anti-diabetic, anti-inflammatory and anti-athrogenic adipocytokine, 
adiponectin. These observations serve to define that some of the key mechanisms 
involved in the maintenance of microvascular tone and to offer a possible approach as 
to how these mechanisms might be therapeutically manipulated. 
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FIGURE LEGENDS  
 
Figure 1. In the upper panels, the time course of coronary resistance (CR) is shown in 
isolated hearts from control (C) and diabetic (D) rats during perfusion at constant 
pressure (P) (80 min at 80 mm Hg) (protocol 1) or transient reduction of perfusion 
pressure (30 min at 20 mm Hg) (protocol 2). In the lower panel, the time course of CR 
during transient reduction of perfusion pressure (protocol 2) is shown for untreated (C 
and D) and CoPP treated (C-CoPP and D-CoPP) animals. Diabetic animals show 
higher coronary resistance, in absolute values, than controls in all the study conditions 
except early reperfusion. Transient reduction of perfusion pressure causes a similar 
percent increase in coronary resistance in both groups which was prevented by CoPP 
treatment. For statistical significance see Table 1. Bas=baseline perfusion pressure (80 
mm Hg); Low P=low perfusion pressure (20 mm Hg); Late RP=last 20 min of 
reperfusion at baseline perfusion pressure (80 mm Hg). Time scale at the onset of Low 
P and of reperfusion has been expanded; p<0.01 diabetic vs. control and diabetic-CoPP 
vs. control-CoPP *p<0.01 vs. baseline; 
#p<0.01 CoPP treated vs. corresponding 
untreated groups. 
 
Figure 2. Myocardial lactate release at different times during transient low perfusion 
pressure experiments in untreated (C and D) and CoPP treated (C-CoPP and D-CoPP) 
animals. Bas=baseline perfusion pressure (80 mm Hg); Low P=low perfusion pressure 
(20 mm Hg); Late RP=last 20 min of reperfusion at baseline perfusion pressure (80 mm 
Hg). Time scale at the onset of Low P and of reperfusion has been expanded. 
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p<0.01 control-CoPP and diabetic-CoPP vs. untreated groups. 
 
Figure 3. HO-1, HO-2 protein levels and HO activity in hearts from control (C) and 
diabetic (D) rats with and without CoPP treatment after perfusion at transient low 
pressure. Mean band density was normalized relative to ￿-actin (n=4 for each group); 
#p<0.05 diabetic vs. control rats; *p<0.01 CoPP-treated groups vs. corresponding 
untreated groups. 
 
Figure 4. Western blot analysis of HO-1, HO-2 protein and ￿-actin in hearts from control 
(C) and diabetic (D) rats after perfusion at transient low pressure. Mean band density 
was normalized relative to ￿-actin; n=4; #p<0.05 diabetic vs. control rats. 
 
Figure 5. Western blot analysis of eNOS, iNOS protein and ￿-actin in hearts after 
perfusion at transient low pressure from untreated control (C) and diabetic (D) rats. 
Mean band density was normalized relative to ￿-actin; n=4; #p<0.05 diabetic vs. control 
rats. 
 
Figure 6. Western blot analysis of eNOS, iNOS protein and ￿-actin in hearts from 
control (C) and diabetic (D) rats with and without CoPP treatment after perfusion at 
transient low pressure. Representative immunoblots are shown (n=4); *p<0.05 eNOS D 
vs. C and iNOS C-CoPP vs. C; **p<0.001 eNOS D-CoPP vs. D and iNOS D-CoPP vs. 
D. 
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Figure 7. Malondialdehyde (MDA) tissue levels measured after transient low perfusion 
pressure in hearts from control and diabetic rats with and without CoPP treatment; 
*p<0.01 CoPP treated groups vs. corresponding untreated groups. 
 
Figure 8.  Measurement of serum adiponectin levels in control and diabetic animals 
before and after CoPP treatment. Adiponectin was determined as described in Methods. 
Results are mean ± SE; n=4. #=p<0.05 diabetic vs. control rats;  *=p<0.01 Diabetic-
CoPP vs. untreated diabetic animals. 
 
Figure 9. Cardiac O2
- levels (upper panel) and expression of p-Akt and Bcl-xL (lower 
panel) in control and diabetic rats with and without CoPP treatment after perfusion at 
transient low pressure. Quantitative densitometry analyses of p-Akt/total Akt ratio and of 
Bcl-xL/actin ratio are shown. #p<0.05 diabetic vs. control rats;*p<0.01 CoPP-treated 
groups vs. corresponding untreated groups. 
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Table 1. Effects of low perfusion pressure and HO-1 upregulation by CoPP on coronary 
resistance in control and diabetic rats 
 
Coronary Resistance (mm Hg·g·min·mL-1) 
Bas  Low PP  Early RP  Late RP 
Control  9.3±0.5 15.8±0.4* 6.2±0.2*  9.6±0.5 
Diabetic  10.5±0.6 16.9±0.5*  7.1±0.3*  12.5±0.5 
Control-CoPP 10.8±0.8
# 10.4±0.3
# 6.0±0.2* 12.8±0.6
#
Diabetic-CoPP 12.7±0.2
# 12±0.2
# 7.4±0.3* 17.9±0.7
#
Bas=baseline perfusion pressure (80 mm Hg); Low PP=low perfusion pressure (20 mm 
Hg); Late RP=last 20 min of reperfusion at baseline perfusion pressure (80 mm Hg). 
p<0.01 diabetic vs. control and diabetic-CoPP vs. control-CoPP at Bas, Low PP and 
Late RP.  
*p<0.01 vs. baseline; 
#p<0.01 CoPP treated vs. corresponding untreated groups 
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